Back to top
more

Sinovac Biotech (SVA)

(Delayed Data from NSDQ)

$6.47 USD

6.47
NA

0.00 (0.00%)

Updated Feb 22, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for SVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Sinovac Biotech, Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 11,228 11,321 13,426 1,185 206
Receivables 451 609 952 253 114
Notes Receivable 0 0 0 0 0
Inventories 140 181 376 106 28
Other Current Assets 12 15 161 16 2
Total Current Assets 11,831 12,126 14,915 1,560 350
Net Property & Equipment 980 994 903 200 74
Investments & Advances 684 661 656 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 30 71 52 27 11
Intangibles 9 10 1 1 0
Deposits & Other Assets 80 194 105 28 10
Total Assets 13,658 14,115 16,748 1,901 452
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 4 2 6 7
Accounts Payable 974 906 1,021 211 59
Current Portion Long-Term Debt 76 0 3 33 6
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 41 0 1,268 35 2
Other Current Liabilities 51 175 110 390 13
Total Current Liabilities 1,148 1,092 2,413 680 87
Mortgages 0 0 0 0 0
Deferred Taxes/Income 264 242 324 3 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 178 12 17 8 1
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 6 5 5 5 6
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,635 1,402 2,872 781 100
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 541 541 548 539 208
Retained Earnings 7,119 7,226 7,142 144 57
Other Equity 4,363 4,946 6,186 437 87
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 12,023 12,713 13,876 1,120 352
Total Liabilities & Shareholder's Equity 13,658 14,115 16,748 1,901 452
Total Common Equity 12,023 12,713 13,876 1,120 352
Shares Outstanding 99.50 99.50 99.50 99.30 98.90
Book Value Per Share 120.83 127.77 139.46 11.28 3.56

Fiscal Year End for Sinovac Biotech, Ltd falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 11,228 -99,999 11,073
Receivables NA NA 451 NA 500
Notes Receivable NA NA 0 NA NA
Inventories NA NA 140 NA 183
Other Current Assets NA NA 12 NA 13
Total Current Assets NA NA 11,831 NA 11,769
Net Property & Equipment NA NA 980 NA 1,059
Investments & Advances NA NA 684 NA 658
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 30 NA 99
Intangibles NA NA 9 NA 9
Deposits & Other Assets NA NA 80 NA 84
Total Assets NA NA 13,658 NA 13,725
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA 0 NA 4
Accounts Payable NA NA 974 NA 820
Current Portion Long-Term Debt NA NA 76 NA 201
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses NA NA 0 NA NA
Income Taxes Payable NA NA 41 NA NA
Other Current Liabilities NA NA 51 NA 159
Total Current Liabilities NA NA 1,148 NA 1,190
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 264 NA 239
Convertible Debt NA NA 0 NA NA
Long-Term Debt NA NA 178 NA 11
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 6 NA 7
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 1,635 NA 1,488
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA 0 NA 0
Common Stock (Par) NA NA 0 NA 0
Capital Surplus NA NA 541 NA 541
Retained Earnings NA NA 7,119 NA 7,240
Other Equity NA NA 4,363 NA 4,456
Treasury Stock NA NA 0 NA NA
Total Shareholder's Equity NA NA 12,023 NA 12,237
Total Liabilities & Shareholder's Equity NA NA 13,658 NA 13,725
Total Common Equity 0 0 12,023 0 12,237
Shares Outstanding 99.60 99.60 99.50 99.50 99.50
Book Value Per Share 0.00 0.00 120.83 0.00 122.99